BCL-2′s pathological role in AML is underscored by the clinical efficacy of the BH3-mimetic venetoclax, which binds the hydrophobic groove of BCL-2 and liberates pro-apoptotic effectors to trigger cell death [24]. This evidence concerns the gene BCL2 and acute myeloid leukemia.